2.695USD-4.26%Mkt Cap: 301.31M USDP/E: —Last update: 2026-06-01
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen r…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap301.31M USD
Enterprise Value232.99M USD
Revenue (TTM)6.32M USD
Gross Profit-81.15M USD
Net Income (TTM)-136.31M USD
Revenue/Share0.0530 USD
Last Price2.695 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees161
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS31189P1021
Valuation
P/E (Trailing)—
P/E (Forward)-3.07
PEG—
EV/EBITDA-1.85
EV/Revenue36.89
P/S52.41
P/B1.84
EPS (TTM)-1.09
EPS (Forward)-0.92
52W Range
0.910091% of range2.880
52W High2.880 USD
52W Low0.9100 USD
Profitability
Gross Margin0.00%
Oper. Margin-2540.42%
EBITDA Margin0.00%
Profit Margin-2051.08%
ROE-65.79%
ROA-42.74%
Growth
Revenue Growth-20.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-106.08M USD
CapEx (TTM)5.95M USD
FCF Margin-792.72%
FCF Yield-16.62%
Net Debt-98.04M USD
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity0.38
Current Ratio5.85
Quick Ratio5.75
Book Value/Sh1.546 USD
Cash/Share1.500 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Target (Mean)5.411 USD
Target Range2.200 USD – 8.000 USD
# Analysts9
Ownership
Shares Out.116.56M
Float101.89M
Insiders1.17%
Institutions72.85%
Short Interest
Short Ratio3.3d
Short % Float9.46%
Short % Out.8.35%
Shares Short9.73M
Short (prev mo.)10.28M
Technical
SMA 501.570 (+71.6%)
SMA 2001.273 (+111.8%)
Beta2.14
S&P 52W Chg27.94%
Avg Vol (30d)3.66M
Avg Vol (10d)4.75M
Technical Indicators
RSI (14)72.6
MACD0.2439
MACD Signal0.1917
MACD Hist.+0.0522
BB Upper2.775 USD
BB Middle2.136 USD
BB Lower1.497 USD
BB Width59.83%
ATR (14)0.2328 USD
Vol Ratio (20d)0.88x